Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teduglutide and Glucose Effect on Plasma Lipoproteins
NCT03860688Phase 3Unknown
- Sponsor
- University Health Network
- Start
- May 2019
- Primary completion
- Dec 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of teduglutide in hyperlipidemia, sponsored by University Health Network. Primary endpoint: Lipoprotein response to teduglutide and glucose at 8 hours. Status: unknown.
02
Drugs
teduglutide
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT03860688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03860688.